Sign In
Buy LLY
$1,125.38
+42.15 (+3.89%)
At Close: Jun 04, 2026
Eli Lilly lining up $1.3bn swoop for cholesterol specialist Verve
04:04am, Tuesday, 17'th Jun 2025
Eli Lilly and Co (NYSE:LLY) is in advanced discussions to acquire Verve Therapeutics in a deal worth up to $1.3 billion, according to the Financial Times. The proposed terms include a nearly $1 billio
Eli Lilly nears $1.3 billion deal for gene-editing biotech Verve Therapeutics, FT reports
07:49pm, Monday, 16'th Jun 2025
Eli Lilly is in advanced talks to acquire gene editing startup Verve Therapeutics for up to $1.3 billion, the Financial Times reported on Monday, citing people familiar with the matter.
Eli Lilly (LLY) Stock Dips While Market Gains: Key Facts
06:46pm, Monday, 16'th Jun 2025
In the closing of the recent trading day, Eli Lilly (LLY) stood at $807.58, denoting a -1.44% move from the preceding trading day.
PFE or LLY: Which Is the Better Value Stock Right Now?
12:41pm, Monday, 16'th Jun 2025
Investors interested in stocks from the Large Cap Pharmaceuticals sector have probably already heard of Pfizer (PFE) and Eli Lilly (LLY). But which of these two stocks is more attractive to value inve
Want a $1 Million Retirement Portfolio? Invest $100,000 in These 3 Stocks and Wait 10 Years
09:25am, Monday, 16'th Jun 2025
Key Points in This Article: Growing a $100,000 investment into a $1 million retirement portfolio in 10 years requires a 25.9% CAGR from high-growth stocks with solid financials.
Lilly to offer higher dose versions of weight-loss drugs on website
07:04am, Monday, 16'th Jun 2025
U.S. drugmaker Eli Lilly said on Monday it will offer the higher dose versions of its popular weight-loss drug Zepbound on its website LillyDirect.
3 Growth Stocks You Can Buy Right Now Without Any Hesitation
07:04am, Monday, 16'th Jun 2025
You're unlikely to have a warm-and-fuzzy feeling after buying some stocks. Instead, some stocks can keep you awake at night because of their high volatility and risk.
Lilly to offer all approved doses of Zepbound (tirzepatide) single-dose vials through LillyDirect Self Pay Pharmacy Solutions
06:45am, Monday, 16'th Jun 2025
With the addition of 12.5 mg and 15 mg vials, all approved doses of Zepbound will be available in single-dose vials for $499/month or less, regardless of insurance status, under Zepbound Self Pay Jour
Eli Lilly Just Made Another Move to Dominate the Weight Loss Market: Should You Buy the Stock?
07:30am, Sunday, 15'th Jun 2025
Eli Lilly (LLY 0.90%) is one of the undisputed leaders in the fast-growing market for weight-management medicines. Following recent clinical wins, the company may even be taking the lead ahead of its
1 Growth Stock Down 9% to Buy Right Now
04:40am, Saturday, 14'th Jun 2025
Not many companies that have been around since the late 1800s can claim that they're growth companies. But Eli Lilly (LLY 0.90%) can.
Eli Lilly's experimental obesity drug shows over 11% weight loss in early trial
06:44pm, Friday, 13'th Jun 2025
Eli Lilly's experimental obesity drug, eloralintide, helped some patients lose 11.5% of their body weight at 12 weeks in an early-stage study, an investor note by brokerage Cantor Fitzgerald showed on
Novo Nordisk Is Europe's Most Valuable Company—Again. Eli Lilly, Watch Out.
12:58pm, Friday, 13'th Jun 2025
The Danish drug maker is being more forceful since its CEO departed last month.
Lilly Moves Past 50-Day Average: Should You Buy the Stock Now?
11:46am, Friday, 13'th Jun 2025
Eli Lilly and Company LLY has reached a significant support level, making it an attractive option for investors from a technical standpoint. Earlier this week, the stock broke through its 50-day simpl
Zepbound Put Eli Lilly On Top — Now Its Next Big Move Could Supercharge The Stock
10:47am, Friday, 13'th Jun 2025
Eli Lilly & Co. LLY may be down over 8% in the past month and nearly 5% over the past five days, but JPMorgan analyst Chris Schott isn't backing off. In fact, he's doubling down.
Down 12%, Should You Buy the Dip on Eli Lilly?
03:10am, Friday, 13'th Jun 2025
Eli Lilly (LLY 0.36%) has been a great growth pick for investors over the past few years. The pharma company, thanks to its weight loss drug portfolio, has seen revenue climb in the double digits -- a
